Skip to main content

Latest Articles

Latest Articles

Showing 9 / 872 Weight Management articles

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®
Metabolic Health

ROOT Brands® Fills GLP-1 Gap with CRUSH™ & SCULPT™ After Ozempic® & Wegovy®

As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.

Shotlee··5 min read
Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains
GLP-1 Medications

Why Semaglutide Pens Cost More Than Vials: OneSource CEO Explains

Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.

Shotlee··5 min read